Retatrutide 15mg

Retatrutide 15 mg research-grade lyophilized peptide powder in a glass vial. Retatrutide (LY3437943), marketed here as Reta-Solution, is an investigational multi-receptor peptide agonist that targets the receptors for GIP, GLP-1 and glucagon, and is used in experimental models of obesity, glycemic control and metabolic regulation. Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use. Purity 99%+ (HPLC, third-party tested) Test Certificate View Certificate of Analysis Form Lyophilized peptide powder Content 15 mg Retatrutide per vial Packaging Glass vial with sterile closure Storage Store lyophilized at 2–8 °C (desiccated, protect from light) Molecular formula C221 H342 N46 O68 Molecular weight ~4731.4 g·mol⁻¹ Sequence Multidomain incretin/glucagon analog (GIP/GLP-1/glucagon triple agonist) peptide backbone with C20 fatty diacid and γGlu–(AEEA)2 side chain for extended PK (Retatrutide, LY3437943). CAS number 2381089-83-2 In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC). For a compatible research-only solvent, see Bacteriostatic water – 10 ml . Research Overview Retatrutide is a next-generation multi-agonist peptide that engages GIP, GLP-1 and glucagon receptors simultaneously. It is used in laboratory and preclinical models to study integrated control of body weight, glucose homeostasis and whole-body energy balance, without implying any therapeutic or clinical use. Primary Research Areas Triple GIP/GLP-1/glucagon receptor agonism: Mechanistic studies dissecting receptor pharmacology, biased signaling and downstream pathways triggered by combined incretin and glucagon receptor activation. Obesity & body-weight regulation models: In vivo models exploring changes in body weight, adiposity, food intake and energy expenditure under Retatrutide-driven multi-agonist signaling. Glycemic control & metabolic health: Research focused on glucose tolerance, insulin dynamics, hepatic glucose output and broader metabolic homeostasis in preclinical systems.